FRI0421 DYSREGULATED MIR-125 PROMOTES JOINT ANGIOGENESIS IN PSA THROUGH ALTERED BIOENERGETICS
Background: Psoriatic arthritis (PsA) is characterised by an early vascular phase which is essential in perpetuating pannus growth, immune responses and disease progression. Recently, numerous studies have highlighted the emerging importance of endothelial cell metabolism in controlling angiogenesis. Herein, we propose microRNA, miR-125, modulates EC bioenergetics and orchestrates joint angiogenesis as characterised using ex-vivo and in-vitro tissue/cell assays and a novel in-vivo zebrafish model. Objectives: To examine the relationship between miR-125, angiogenesis and cellular metabolism in the PsA synovium. Methods: Primary PsA synovial fibroblasts (PsA FLS) and microvascular endothelial cells (HMVEC) were transfected with anti-miR-125a. Angiogenic mechanisms were quantified using tube formation assays, invasion by Transwell Matrigel chambers, migration by wound repair and metabolic gene expression by RT-PCR. Real-time analysis of extracellular acidification rates (ECAR) and oxygen consumption rates (OCR) of anti-125 treated HMVEC was assessed using the XF-24 Flux Analyzer (Seahorse Bioscience). To determine if altered metabolism is observed ex vivo, glycolysis/oxidative phosphorylation markers (GAPDH/PKM2/GLUT1/ATP), and angiogenic factors (FactorVIII/VEGF/ANG2) were quantified by immunohistology. MiRNA levels were quantified in synovial tissue (ST) and PBMC by RT-PCR and compared to clinical marker and immunohistochemical analysis. The angiogenic effects of miR-125 were assessed in vivo using GFP-tagged zebrafish embryos treated with anti-125 morpholinos, or vitamin D3 analog, calcitrol, to monitor vascular development. Results: An increase in tube formation, cellular invasion and/or migration mechanisms (p<0.05) were demonstrated in anti-miR-125a transfected HMVEC and FLS supernatant. Inhibition of miR-125 significantly decreased basal, maximal and spare respiratory capacity (P<0.009) with a concurrent decrease in ATP synthesis (P<0.008). Increased glycolysis was further confirmed by the observed elevation of glycolytic genes: HK2, GSK3A, PDK1, HP6G (ns) and 3PO target and stimulator of glycolysis, PFKFB3 (P<0.05). In vivo synovial expression of miR-125 was significantly decreased in PsA versus OA synovial tissue and was associated with increased PsA macroscopic and microscopic vascularity. This was paralleled by a significant increase in the vascular expression of glycolytic markers, PKM2, GLUT1 and ATP5B in PsA compared to OA synovium. Finally, anti-125 morpholinos treated Zebrafish displayed increased vascular sprouting. In contrast, Calcitriol significantly reduced vascular development and increased the expression of miR-125, promoting miR-125 as a potential mechanism for orchestrating angiogenic development in vivo and in response to pharmaceutical agents Conclusions: Our data demonstrates decreased expression of miR-125 in PsA synovium and in-vivo models was strongly associated pro-angiogenic mechanisms. Elevated glycolysis following miR-125 inhibition may enables endothelial cells to meet the increased energy and biosynthetic demands for new vessel formation. Correcting these deficiencies and their resulting metabolic shift, either by conventional pharmacological or as novel drug targets, may provide therapeutic benefit, especially in early disease. Background: Spondyloarthritis (SpA) are an inflammatory joint disease with chronic, progressive, axial inflammation of the spine and the sacroiliac joints. Diagnosis of SpA is done criteria by clinical symptoms, radiology and MRI or ultrasound following ASAS criteria. AS is similar to rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as they are all inflammatory joint disease. Nevertheless they show considerable different pathology.
[1] Objectives: The aim of our study is to test whether a novel assay that we developed for RA can be used for SpA diagnosis. We have previously showed that antibodies to oxidative post-translationally modified collagen type II (oxPTM-CII) are present specifically in RA patients whether ACPA positive or negative.
[2] Our study intends to investigate the reactivity to oxPTM-CII in SpA patients in comparison to early undifferentiated arthritis (EUA) and PsA patients. Methods: oxPTM-CII were generated using ribose and various reactive oxidants, and then they were analysed by SDS-PAGE. Binding to native and oxPTM-CII was evaluated by ELISA and Western Blotting. We used a cohort of sera from 67 patients with SpA, 54 patients with PsA, 49 patients with EUA. As control we used 19 patients with fibromyalgia (FM) and 70 healthy subjects. The specificity of the binding was further assessed by competitive ELISA and western blot. Results: We detected stronger reactivity to SpA compared to PsA and even EUA serum samples. Hence specific binding to oxPTM-CII was seen in the 52% of SpA sera compared to 12% in PsA and 10% in EUA. There was no binding in samples from FM and healthy individuals. A group of the most reactive SpA samples was evaluated by western blot confirming a strong binding to several fragments or aggregates of oxPTM-CII.
Conclusions:
For the first time we demonstrated that anti-ROS-CII may become a biomarker for SpA diagnosis. 
